LYMPHOSYNCHRO
Withdrawn
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Phase 1 Withdrawn
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Phase 1 Withdrawn
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Phase NA Withdrawn
FIL_POLARDHAP
Phase 2 Withdrawn
CAR19T2
Phase 1/2 Withdrawn
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
Phase 1 Withdrawn
Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
Phase NA Withdrawn
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
Phase 1/2 Withdrawn
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Phase 1/2 Withdrawn
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Phase 1 Withdrawn
CD19-targeting CAR T Cells for B Cell Lymphoma
Phase 1/2 Withdrawn
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
Phase 1 Withdrawn
Bone Marrow Transplantation in Treating Patients With Leukemia
Phase 3 Withdrawn
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
Phase 2 Withdrawn
A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma
Phase 2 Withdrawn
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
Phase 1 Withdrawn
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
Phase NA Withdrawn
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase 1/2 Withdrawn
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
Phase 2 Withdrawn
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
Phase 2 Withdrawn
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Phase 2 Withdrawn
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 2 Withdrawn
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Withdrawn
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Phase 1 Withdrawn
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Phase 2 Withdrawn
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2 Withdrawn
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
Phase NA Withdrawn
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Phase 1/2 Withdrawn
Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.
Phase 1/2 Withdrawn
Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)
Phase 2 Withdrawn
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
Phase NA Withdrawn
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
Phase 2 Withdrawn
LYMPHOS
Phase 4 Withdrawn
EBUS-TBNA Versus EBUS-TBNB
Phase NA Withdrawn
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
Phase 1/2 Withdrawn
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
Phase 1 Withdrawn
Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma
Phase 1/2 Withdrawn
Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL
Phase 2 Withdrawn
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma
Phase 1/2 Withdrawn
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Phase 2 Withdrawn
Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Withdrawn
The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
Withdrawn
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
Phase 2 Withdrawn
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
Withdrawn
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Withdrawn
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly
Phase NA Withdrawn
Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer
Phase 1 Withdrawn